Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
26
NLH.V Quote, Financials, Valuation and Earnings
Last price:
$0.28
Seasonality move
:
-4.27%
Day range:
$0.28 - $0.28
52-week range:
$0.22 - $0.35
Dividend yield:
0%
P/E ratio:
23.53x
P/S ratio:
0.59x
P/B ratio:
0.94x
Volume:
221.6K
Avg. volume:
19.6K
1-year change:
--
Market cap:
$24.4M
Revenue:
$35.3M
EPS (TTM):
$0.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NLH.V
Nova Leap Health Corp.
|
$9.2M | -- | 10.72% | -100% | -- |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
-- | -- | -- | -- | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NLH.V
Nova Leap Health Corp.
|
$0.28 | -- | $24.4M | 23.53x | $0.00 | 0% | 0.59x |
|
COOL.CX
Core One Labs, Inc.
|
$0.15 | -- | $6.8M | -- | $0.00 | 0% | 32.71x |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
HEAL.CX
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
$0.05 | -- | $9.7M | -- | $0.00 | 0% | -- |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
$0.0200 | -- | $205.5K | 0.52x | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NLH.V
Nova Leap Health Corp.
|
13.83% | 1.730 | 15.23% | 0.87x |
|
COOL.CX
Core One Labs, Inc.
|
-- | 0.000 | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | 0.000 | -- | -- |
|
HEAL.CX
|
-- | 0.000 | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
40.99% | -3.518 | 19.05% | 2.85x |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-3.43% | 1.456 | 20.53% | 0.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NLH.V
Nova Leap Health Corp.
|
$4.2M | $576.5K | 3.54% | 4.05% | 5.07% | $592.1K |
|
COOL.CX
Core One Labs, Inc.
|
-- | -- | -- | -- | -- | -- |
|
CURE.X.CX
Biocure Technology
|
-- | -- | -- | -- | -- | -- |
|
HEAL.CX
|
-- | -- | -- | -- | -- | -- |
|
LOBE.CX
Lobe Sciences Ltd.
|
-- | -$1.1M | -1117.27% | -- | -- | -$408.2K |
|
NSHS.CX
NanoSphere Health Sciences, Inc.
|
-- | -$72.1K | -- | -- | -- | -$92.1K |
Nova Leap Health Corp. vs. Competitors
-
Which has Higher Returns NLH.V or COOL.CX?
Core One Labs, Inc. has a net margin of 5.16% compared to Nova Leap Health Corp.'s net margin of --. Nova Leap Health Corp.'s return on equity of 4.05% beat Core One Labs, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NLH.VNova Leap Health Corp.36.78% $0.01 $30.3M COOL.CXCore One Labs, Inc.-- -- -- -
What do Analysts Say About NLH.V or COOL.CX?
Nova Leap Health Corp. has a consensus price target of --, signalling upside risk potential of 114.08%. On the other hand Core One Labs, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Nova Leap Health Corp. has higher upside potential than Core One Labs, Inc., analysts believe Nova Leap Health Corp. is more attractive than Core One Labs, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NLH.VNova Leap Health Corp.0 0 0 COOL.CXCore One Labs, Inc.0 0 0 -
Is NLH.V or COOL.CX More Risky?
Nova Leap Health Corp. has a beta of 1.632, which suggesting that the stock is 63.171% more volatile than S&P 500. In comparison Core One Labs, Inc. has a beta of 0.495, suggesting its less volatile than the S&P 500 by 50.458%.
-
Which is a Better Dividend Stock NLH.V or COOL.CX?
Nova Leap Health Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Core One Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nova Leap Health Corp. pays -- of its earnings as a dividend. Core One Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NLH.V or COOL.CX?
Nova Leap Health Corp. quarterly revenues are $11.4M, which are larger than Core One Labs, Inc. quarterly revenues of --. Nova Leap Health Corp.'s net income of $587K is higher than Core One Labs, Inc.'s net income of --. Notably, Nova Leap Health Corp.'s price-to-earnings ratio is 23.53x while Core One Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nova Leap Health Corp. is 0.59x versus 32.71x for Core One Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NLH.VNova Leap Health Corp.0.59x 23.53x $11.4M $587K COOL.CXCore One Labs, Inc.32.71x -- -- --
-
Which has Higher Returns NLH.V or CURE.X.CX?
Biocure Technology has a net margin of 5.16% compared to Nova Leap Health Corp.'s net margin of --. Nova Leap Health Corp.'s return on equity of 4.05% beat Biocure Technology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NLH.VNova Leap Health Corp.36.78% $0.01 $30.3M CURE.X.CXBiocure Technology-- -- -- -
What do Analysts Say About NLH.V or CURE.X.CX?
Nova Leap Health Corp. has a consensus price target of --, signalling upside risk potential of 114.08%. On the other hand Biocure Technology has an analysts' consensus of -- which suggests that it could fall by --. Given that Nova Leap Health Corp. has higher upside potential than Biocure Technology, analysts believe Nova Leap Health Corp. is more attractive than Biocure Technology.
Company Buy Ratings Hold Ratings Sell Ratings NLH.VNova Leap Health Corp.0 0 0 CURE.X.CXBiocure Technology0 0 0 -
Is NLH.V or CURE.X.CX More Risky?
Nova Leap Health Corp. has a beta of 1.632, which suggesting that the stock is 63.171% more volatile than S&P 500. In comparison Biocure Technology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NLH.V or CURE.X.CX?
Nova Leap Health Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biocure Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nova Leap Health Corp. pays -- of its earnings as a dividend. Biocure Technology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NLH.V or CURE.X.CX?
Nova Leap Health Corp. quarterly revenues are $11.4M, which are larger than Biocure Technology quarterly revenues of --. Nova Leap Health Corp.'s net income of $587K is higher than Biocure Technology's net income of --. Notably, Nova Leap Health Corp.'s price-to-earnings ratio is 23.53x while Biocure Technology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nova Leap Health Corp. is 0.59x versus -- for Biocure Technology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NLH.VNova Leap Health Corp.0.59x 23.53x $11.4M $587K CURE.X.CXBiocure Technology-- -- -- --
-
Which has Higher Returns NLH.V or HEAL.CX?
has a net margin of 5.16% compared to Nova Leap Health Corp.'s net margin of --. Nova Leap Health Corp.'s return on equity of 4.05% beat 's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NLH.VNova Leap Health Corp.36.78% $0.01 $30.3M HEAL.CX-- -- -- -
What do Analysts Say About NLH.V or HEAL.CX?
Nova Leap Health Corp. has a consensus price target of --, signalling upside risk potential of 114.08%. On the other hand has an analysts' consensus of -- which suggests that it could fall by --. Given that Nova Leap Health Corp. has higher upside potential than , analysts believe Nova Leap Health Corp. is more attractive than .
Company Buy Ratings Hold Ratings Sell Ratings NLH.VNova Leap Health Corp.0 0 0 HEAL.CX0 0 0 -
Is NLH.V or HEAL.CX More Risky?
Nova Leap Health Corp. has a beta of 1.632, which suggesting that the stock is 63.171% more volatile than S&P 500. In comparison has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NLH.V or HEAL.CX?
Nova Leap Health Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nova Leap Health Corp. pays -- of its earnings as a dividend. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NLH.V or HEAL.CX?
Nova Leap Health Corp. quarterly revenues are $11.4M, which are larger than quarterly revenues of --. Nova Leap Health Corp.'s net income of $587K is higher than 's net income of --. Notably, Nova Leap Health Corp.'s price-to-earnings ratio is 23.53x while 's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nova Leap Health Corp. is 0.59x versus -- for . Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NLH.VNova Leap Health Corp.0.59x 23.53x $11.4M $587K HEAL.CX-- -- -- --
-
Which has Higher Returns NLH.V or LOBE.CX?
Lobe Sciences Ltd. has a net margin of 5.16% compared to Nova Leap Health Corp.'s net margin of --. Nova Leap Health Corp.'s return on equity of 4.05% beat Lobe Sciences Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NLH.VNova Leap Health Corp.36.78% $0.01 $30.3M LOBE.CXLobe Sciences Ltd.-- -$0.01 $5.9M -
What do Analysts Say About NLH.V or LOBE.CX?
Nova Leap Health Corp. has a consensus price target of --, signalling upside risk potential of 114.08%. On the other hand Lobe Sciences Ltd. has an analysts' consensus of -- which suggests that it could grow by 14192.33%. Given that Lobe Sciences Ltd. has higher upside potential than Nova Leap Health Corp., analysts believe Lobe Sciences Ltd. is more attractive than Nova Leap Health Corp..
Company Buy Ratings Hold Ratings Sell Ratings NLH.VNova Leap Health Corp.0 0 0 LOBE.CXLobe Sciences Ltd.0 0 0 -
Is NLH.V or LOBE.CX More Risky?
Nova Leap Health Corp. has a beta of 1.632, which suggesting that the stock is 63.171% more volatile than S&P 500. In comparison Lobe Sciences Ltd. has a beta of 0.215, suggesting its less volatile than the S&P 500 by 78.507%.
-
Which is a Better Dividend Stock NLH.V or LOBE.CX?
Nova Leap Health Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lobe Sciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nova Leap Health Corp. pays -- of its earnings as a dividend. Lobe Sciences Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NLH.V or LOBE.CX?
Nova Leap Health Corp. quarterly revenues are $11.4M, which are larger than Lobe Sciences Ltd. quarterly revenues of --. Nova Leap Health Corp.'s net income of $587K is higher than Lobe Sciences Ltd.'s net income of -$1.1M. Notably, Nova Leap Health Corp.'s price-to-earnings ratio is 23.53x while Lobe Sciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nova Leap Health Corp. is 0.59x versus -- for Lobe Sciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NLH.VNova Leap Health Corp.0.59x 23.53x $11.4M $587K LOBE.CXLobe Sciences Ltd.-- -- -- -$1.1M
-
Which has Higher Returns NLH.V or NSHS.CX?
NanoSphere Health Sciences, Inc. has a net margin of 5.16% compared to Nova Leap Health Corp.'s net margin of --. Nova Leap Health Corp.'s return on equity of 4.05% beat NanoSphere Health Sciences, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NLH.VNova Leap Health Corp.36.78% $0.01 $30.3M NSHS.CXNanoSphere Health Sciences, Inc.-- -$0.00 -$1.8M -
What do Analysts Say About NLH.V or NSHS.CX?
Nova Leap Health Corp. has a consensus price target of --, signalling upside risk potential of 114.08%. On the other hand NanoSphere Health Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Nova Leap Health Corp. has higher upside potential than NanoSphere Health Sciences, Inc., analysts believe Nova Leap Health Corp. is more attractive than NanoSphere Health Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NLH.VNova Leap Health Corp.0 0 0 NSHS.CXNanoSphere Health Sciences, Inc.0 0 0 -
Is NLH.V or NSHS.CX More Risky?
Nova Leap Health Corp. has a beta of 1.632, which suggesting that the stock is 63.171% more volatile than S&P 500. In comparison NanoSphere Health Sciences, Inc. has a beta of 0.627, suggesting its less volatile than the S&P 500 by 37.292%.
-
Which is a Better Dividend Stock NLH.V or NSHS.CX?
Nova Leap Health Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoSphere Health Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nova Leap Health Corp. pays -- of its earnings as a dividend. NanoSphere Health Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NLH.V or NSHS.CX?
Nova Leap Health Corp. quarterly revenues are $11.4M, which are larger than NanoSphere Health Sciences, Inc. quarterly revenues of --. Nova Leap Health Corp.'s net income of $587K is higher than NanoSphere Health Sciences, Inc.'s net income of -$13.1K. Notably, Nova Leap Health Corp.'s price-to-earnings ratio is 23.53x while NanoSphere Health Sciences, Inc.'s PE ratio is 0.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nova Leap Health Corp. is 0.59x versus -- for NanoSphere Health Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NLH.VNova Leap Health Corp.0.59x 23.53x $11.4M $587K NSHS.CXNanoSphere Health Sciences, Inc.-- 0.52x -- -$13.1K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 40.26% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 4.56% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 3.19% over the past day.
